Search results
Pfizer pauses phase 3 dosing in gene therapy trial after young boy's death
FierceBiotech· 7 hours agoA young boy with Duchenne muscular dystrophy (DMD) participating in Pfizer’s phase 2 gene therapy...
Do These 3 Checks Before Buying Pfizer Inc. (NYSE:PFE) For Its Upcoming Dividend
Simply Wall St. via Yahoo Finance· 4 days agoReaders hoping to buy Pfizer Inc. (NYSE:PFE) for its dividend will need to make their move shortly,...
Pfizer Pauses Gene Therapy Trial for Muscle Disease After Death
Bloomberg· 7 hours agoPfizer Inc. paused a study of an experimental gene therapy for muscular dystrophy after a child who...
Pfizer reports patient death in Duchenne gene therapy study
Reuters via Yahoo News· 7 hours ago(Reuters) -A young patient died due to cardiac arrest after receiving Pfizer's experimental gene...
Pfizer wants the $75 mln left from SAC Capital’s insider trading settlement with SEC
Reuters· 7 hours agoPharma company Pfizer told a New York federal judge on Monday that it is entitled to recoup about...
Patient dies in Pfizer study of Duchenne gene therapy
BioPharma Dive via Yahoo Finance· 11 hours agoPfizer said the patient, a young boy who was treated earlier last year, had died suddenly. The...
AstraZeneca withdrawing Covid vaccine, months after admitting rare side effect
The Telegraph via Yahoo News· 7 hours agoThe Oxford-AstraZeneca Covid vaccine is being withdrawn worldwide, months after the pharmaceutical...
Pfizer First Quarter 2024 Earnings: Beats Expectations
Simply Wall St. via Yahoo Finance· 17 hours agoPfizer (NYSE:PFE) First Quarter 2024 Results Key Financial Results Revenue: US$14.9b (down 19% from...
Is Pfizer Stock Fully Valued At $28?
Forbes· 23 hours agoPfizer (NYSE: PFE) reported its Q1 results last week, with revenues and earnings beating the street estimates.
Leerink Partnrs Comments on Pfizer Inc.’s Q2 2024 Earnings (NYSE:PFE)
ETF DAILY NEWS· 1 day agoPfizer Inc. (NYSE:PFE – Free Report) – Stock analysts at Leerink Partnrs upped their Q2 2024 earnings estimates for Pfizer in a report issued on Thursday ...